HZNP(Delisted)
Horizon Therapeutics Public·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HZNP
Horizon Therapeutics Public Limited Company
A company that developing therapeutics for the treatment of rare and rheumatic diseases
70 St. Stephen’s Green, Dublin 2, D02 E2X4, Ireland
--
Horizon Therapeutics Public Limited Company is a specialized pharmaceutical company specializing in DUEXIS, VIMOVO and RAYOS/LODOTRA. These drugs are mainly aimed at the treatment of arthritis, pain and inflammatory diseases. The company developed DUEXIS and RAYOS/LODOTRA, and in November 2013, acquired the ownership of VIMOVO in the United States from AstraZeneca. The company's strategy is to develop, obtain patents or licenses for additional innovative drugs, or obtain companies that can acquire specialized targeted physicians (such as primary care physicians, orthopedic physicians and rheumatologists), while leveraging the company's commercial advantages and the infrastructure in place to implement targeted commercial approaches. Horizon Pharma Public Limited Company was incorporated in Delaware on March 23, 2010 and re-incorporated in Ireland.
Company Financials
EPS
HZNP has released its 2023 Q2 earnings. EPS was reported at 1.2, versus the expected 1.12, beating expectations. The chart below visualizes how HZNP has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HZNP has released its 2023 Q2 earnings report, with revenue of 944.96M, reflecting a YoY change of 7.82%, and net profit of 127.07M, showing a YoY change of 108.40%. The Sankey diagram below clearly presents HZNP's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
